Drug Trial Radar · NCT00004196
Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis
Last checked: Nov 20, 2026Latest source record: Jan 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,000
Planned (sponsor's estimate)
Start
Oct 1999
Primary completion
Oct 2004
Study completion Nov 2007
Sponsor
- Lead sponsor
- University of Alabama at BirminghamAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jan 27, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Interferon alfa-2b may interfere with the growth of cancer cells. PURPOSE: Randomized phase III trial to study the effectiveness of interferon alfa-2b in treating patients who have melanoma with early lymph node metastasis.
Conditions
- Melanoma (Skin)
Interventions
recombinant interferon alfaBiological
lymphangiographyProcedure
ObservationDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama
James Graham Brown Cancer Center at University of Louisville
Louisville, Kentucky
Cancer Institute of New Jersey
New Brunswick, New Jersey
Roswell Park Cancer Institute
Buffalo, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.